1. |
Assche GV, Ranst PD, RafSciot PD, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med, 2005, 353: 1-7.
|
2. |
Demasters BK , Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med, 2005, 353: 369-374.
|
3. |
Gould A, Atlas S, Green AJ, et al. Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med, 2005, 353: 375-381.
|
4. |
Hartung HP . New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol, 2009, 8: 28-31.
|
5. |
U.S. Department of Health and Human Services. Center for Drug Evaluation and Research 2002 Report to the Nation Improving Public Health Through Human Drugs [cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/downloads/AboutFDA/ CentersOffices/CDER/WhatWeDo/UCM078985.pdf.
|
6. |
U.S. Department of Health and Human Services. Center for Drug Evaluation and Research 2003 Report to the NationReport to the Nation Improving Public Health Through Human Drugs[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/downloads/ AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078975.pdf. U.S. Department of Health and Human Services.
|
7. |
U.S. Department of Health and Human Services.Center for Drug Evaluation and Research 2004 Report to the NationReport to the Nation Improving Public Health Through Human Drugs[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/downloads/ AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078941.pdf..
|
8. |
U.S. Department of Health and Human Services.Center for Drug Evaluation and Research 2005 Report to the NationReport to the Nation Improving Public Health Through Human Drugs[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/downloads/ AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078935.pdf.
|
9. |
U.S. Department of Health and Human Services.Center for Drug Evaluation and Research UPDAE[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/downloads/AboutFDA/ CentersOffices/CDER/WhatWeDo/UCM121704.pdf.
|
10. |
NME Drug and New Biologic Approvals in 2002[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/Drugs/Developmen tApprovalProcess/HowDrugsareDevelopedandApproved/Drugan dBiologicApprovalReports/NMEDrugandNewBiologicApprovals/ ucm081683.htm.
|
11. |
NME Drug and New Biologic Approvals in 2003[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/Drugs/Developmen tApprovalProcess/HowDrugsareDevelopedandApproved/Drugan dBiologicApprovalReports/NMEDrugandNewBiologicApprovals/ ucm081680.htm.
|
12. |
NME Drug and New Biologic Approvals in 2004[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/Drugs/Developmen tApprovalProcess/HowDrugsareDevelopedandApproved/Drugan dBiologicApprovalReports/NMEDrugandNewBiologicApprovals/ ucm081677.htm.
|
13. |
NME Drug and New Biologic Approvals in 2005[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/Drugs/Developmen tApprovalProcess/HowDrugsareDevelopedandApproved/Drugan dBiologicApprovalReports/NMEDrugandNewBiologicApprovals/ ucm081676.htm.
|
14. |
NME Drug and New Biologic Approvals in 2006[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/Drugs/Developmen tApprovalProcess/HowDrugsareDevelopedandApproved/Drugan dBiologicApprovalReports/NMEDrugandNewBiologicApprovals/ ucm081673.htm.
|
15. |
NME Drug and New Biologic Approvals in [cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/Drugs/DevelopmentA pprovalProcess/HowDrugsareDevelopedandApproved/Drugand BiologicApprovalReports/NMEDrugandNewBiologicApprovals/ ucm081690.htm 2007.
|
16. |
CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008 Updated through November 30, 2008[cited 2009, Aug, 15]. Available from: URL: http://www.fda. gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsare DevelopedandApproved/DrugandBiologicApprovalReports/NMEDr ugandNewBiologicApprovals/UCM081805.pdf.
|
17. |
CDER Approval Times for Priority and Standard NMEs and New BLAs CY 1993 – 2008[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProces s/HowDrugsareDevelopedandApproved/DrugandBiologicApproval Reports/UCM123959.pdf.
|
18. |
Fast Track, Accelerated Approval and Priority Review[cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/ForConsumers/ ByAudience/ForPatientAdvocates/SpeedingAccesstoImportantNew Therapies/ucm128291.htm.
|
19. |
杜蕾. 新药的快速审批及风险. 上海食品药品监管情报研究, 2007, (87): 1-4, 47.
|
20. |
Shankar G, Pendley C, Stein KE. A risk—based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol, 2007, 25(5):555-561.
|
21. |
Baumann A. Early development of therapeutic biologics– pharmacokinetics. Curr DrugMetab, 2006, 7(1): 15-21.
|
22. |
Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther, 2007, 82(2): 143-156.
|
23. |
Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ, 2004, 329(7456): 44-47.
|
24. |
Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union. JAMA, 2008, 300(16): 1887-1896.
|
25. |
FDA Issues Final Risk Minimization Guiances[EB/OL]. [cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/bbs/topics/ news/2005/NEW01169.html.
|
26. |
Yousry TA, Habil M, Major EO, et al. Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy. N Engl J Med, 2006, 354: 924-933.
|
27. |
Information on Natalizumab (marketed as Tysabri). [cited 2009, Aug, 15]. Available from: URL: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvid ers/ucm107198.htm.
|
28. |
Tysabri Relaunch Solid, As Efficacy Trumps Risk. [cited 2009, Aug, 15]. Available from: URL: (http://blogs.wsj.com/health/2008/02/29/ tysabri-relaunch-solid-as-efficacy-trumps-risk/).
|
29. |
Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol, 2006, 24(7): 769-776.
|
30. |
Aggarwal S. What’s fueling the biotech engine? Nat Biotechnol, 2007, 25(10): 1097-2011.
|